GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes.
Diabetes
GIP
GLP1
Incretin
Tirzepatide
Journal
Acta diabetologica
ISSN: 1432-5233
Titre abrégé: Acta Diabetol
Pays: Germany
ID NLM: 9200299
Informations de publication
Date de publication:
03 Jun 2024
03 Jun 2024
Historique:
received:
13
02
2024
accepted:
04
05
2024
medline:
4
6
2024
pubmed:
4
6
2024
entrez:
3
6
2024
Statut:
aheadofprint
Résumé
Type 2 diabetes represents a growing challenge for global public health. Its prevalence is increasing worldwide, and, like obesity, it affects progressively younger populations compared to the past, with potentially greater impact on chronic complications. Dual glucagon like peptide 1 (GLP1) and glucose-dependent insulinotropic peptide (GIP) receptor agonists are among the new pharmacological strategies recently developed to address this challenge. Tirzepatide, characterized by its ability to selectively bind and activate receptors for the intestinal hormones GIP and GLP-1, has been tested in numerous clinical studies and is already currently authorized in several countries for the treatment of type 2 diabetes and obesity. In this context, the aim of the present document is to summarize, in the form of a narrative literature review, the currently available data on the main mechanisms of action of GIP/GLP-1 co-agonists and the clinical effects of tirzepatide evaluated in various clinical trials.
Identifiants
pubmed: 38831203
doi: 10.1007/s00592-024-02300-6
pii: 10.1007/s00592-024-02300-6
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Istituto Superiore di Sanità (2021) Dati Sorveglianza PASSI 2020–2021. 2023
Ludvik B, Giorgino F, Jodar E et al (2021) Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet 398(10300):583–598. https://doi.org/10.1016/S0140-6736(21)01443-4
doi: 10.1016/S0140-6736(21)01443-4
pubmed: 34370970
Frias JP, Davies MJ, Rosenstock J et al (2021) Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 385(6):503–515. https://doi.org/10.1056/NEJMoa2107519
doi: 10.1056/NEJMoa2107519
pubmed: 34170647
Jastreboff AM, Aronne LJ, Ahmad NN et al (2022) Tirzepatide once weekly for the treatment of obesity. N Engl J Med 387(3):205–216. https://doi.org/10.1056/NEJMoa2206038
doi: 10.1056/NEJMoa2206038
pubmed: 35658024
Deganutti G, Liang Y-L, Zhang X et al (2022) Dynamics of GLP-1R peptide agonist engagement are correlated with kinetics of G protein activation. Nat Commun 13(1):92
doi: 10.1038/s41467-021-27760-0
pubmed: 35013280
pmcid: 8748714
Laurindo LF, Barbalho SM, Guiguer EL et al (2022) GLP-1a: going beyond traditional use. Int J Mol Sci 23(2):739
doi: 10.3390/ijms23020739
pubmed: 35054924
pmcid: 8775408
Mezza T, Cinti F, Cefalo CMA, Pontecorvi A, Kulkarni RN, Giaccari A (2019) β-cell fate in human insulin resistance and type 2 diabetes: a perspective on islet plasticity. Diabetes 68(6):1121–1129
doi: 10.2337/db18-0856
pubmed: 31109941
pmcid: 6905483
Grespan E, Giorgino T, Natali A, Ferrannini E, Mari A (2021) Different mechanisms of GIP and GLP-1 action explain their different therapeutic efficacy in type 2 diabetes. Metabolism 114:154415
doi: 10.1016/j.metabol.2020.154415
pubmed: 33137379
Budd J, Cusi K (2020) Role of agents for the treatment of diabetes in the management of nonalcoholic fatty liver disease. Curr DiabRep 20:1–9
Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Targher G (2021) Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials. Metabolites 11(2):73
doi: 10.3390/metabo11020073
pubmed: 33513761
pmcid: 7911747
Seghieri M, Rebelos E, Gastaldelli A et al (2013) Direct effect of GLP-1 infusion on endogenous glucose production in humans. Diabetologia 56:156–161
doi: 10.1007/s00125-012-2738-3
pubmed: 23064290
Gastaldelli A, Gaggini M, Daniele G et al (2016) Exenatide improves both hepatic and adipose tissue insulin resistance: a dynamic positron emission tomography study. Hepatology 64(6):2028–2037
doi: 10.1002/hep.28827
pubmed: 27639082
Wachsmuth HR, Weninger SN, Duca FA (2022) Role of the gut–brain axis in energy and glucose metabolism. Exp Mol Med 54(4):377–392
doi: 10.1038/s12276-021-00677-w
pubmed: 35474341
pmcid: 9076644
Clemmensen C, Müller TD, Woods SC, Berthoud H-R, Seeley RJ, Tschöp MH (2017) Gut-brain cross-talk in metabolic control. Cell 168(5):758–774
doi: 10.1016/j.cell.2017.01.025
pubmed: 28235194
pmcid: 5839146
Frias JP, Bonora E, Nevarez Ruiz L et al (2021) Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11). Diabetes Care 44(3):765–773
doi: 10.2337/dc20-1473
pubmed: 33397768
pmcid: 7896253
Kim WJ, Lee SJ, Lee E, Lee EY, Han K (2022) Risk of incident dementia according to glycemic status and comorbidities of hyperglycemia: a nationwide population-based cohort study. Diabetes Care 45(1):134–141
doi: 10.2337/dc21-0957
pubmed: 34711638
Koekkoek PS, Kappelle LJ, van den Berg E, Rutten GE, Biessels GJ (2015) Cognitive function in patients with diabetes mellitus: guidance for daily care. Lancet Neurol 14(3):329–340
doi: 10.1016/S1474-4422(14)70249-2
pubmed: 25728442
Biessels GJ, Verhagen C, Janssen J et al (2019) Effect of linagliptin on cognitive performance in patients with type 2 diabetes and cardiorenal comorbidities: the CARMELINA randomized trial. Diabetes Care 42(10):1930–1938
doi: 10.2337/dc19-0783
pubmed: 31399442
Lunghi C, Daniele G, Binda P et al (2019) Altered visual plasticity in morbidly obese subjects. Iscience 22:206–213
doi: 10.1016/j.isci.2019.11.027
pubmed: 31785558
pmcid: 6909220
Animali S, Steinwurzel C, Dardano A et al (2023) Effect of fasting on short-term visual plasticity in adult humans. Eur J Neurosci 57(1):148–162
doi: 10.1111/ejn.15873
pubmed: 36437778
Daniele G, Iozzo P, Molina-Carrion M et al (2015) Exenatide regulates cerebral glucose metabolism in brain areas associated with glucose homeostasis and reward system. Diabetes 64(10):3406–3412
doi: 10.2337/db14-1718
pubmed: 26116695
pmcid: 6908417
Cukierman-Yaffe T, Gerstein HC, Colhoun HM et al (2020) Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. Lancet Neurol 19(7):582–590
doi: 10.1016/S1474-4422(20)30173-3
pubmed: 32562683
Onaolapo AY, Ojo FO, Adeleye OO, Falade J, Onaolapo OJ (2023) Diabetes mellitus and energy dysmetabolism in Alzheimer’s disease: understanding the relationships and potential therapeutic targets. Curr Diabetes Rev 19:31–45
doi: 10.2174/1573399819666230102141154
Gejl M, Gjedde A, Egefjord L et al (2016) In Alzheimer’s disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial. Front Aging Neurosci 108:198350
Athauda D, Maclagan K, Skene SS et al (2017) Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet 390(10103):1664–1675
doi: 10.1016/S0140-6736(17)31585-4
pubmed: 28781108
pmcid: 5831666
Athauda D, Gulyani S, Kumar Karnati H et al (2019) Utility of neuronal-derived exosomes to examine molecular mechanisms that affect motor function in patients with Parkinson disease: a secondary analysis of the exenatide-PD trial. JAMA Neurol 76(4):420–429
doi: 10.1001/jamaneurol.2018.4304
pubmed: 30640362
pmcid: 6459135
Brown JC, Dryburgh JR (1971) A gastric inhibitory polypeptide II: the complete amino acid sequence. Can J Biochem 49(8):867–872
doi: 10.1139/o71-122
pubmed: 5120249
Brown J, Dryburgh J, Ross S, Dupre J (1975) Identification and actions of gastric inhibitory polypeptide. In: Proceedings of the 1974 Laurentian hormone conference, Elsevier, pp 487–532
Dupre J, Ross S, Watson D, Brown J (1973) Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 37(5):826–828
doi: 10.1210/jcem-37-5-826
pubmed: 4749457
Elahi D, Andersen DK, Brown JC et al (1979) Pancreatic alpha-and beta-cell responses to GIP infusion in normal man. Am J Physiol 237(2):E185-191. https://doi.org/10.1152/ajpendo.1979.237.2.E185
doi: 10.1152/ajpendo.1979.237.2.E185
pubmed: 464094
Christensen M, Vedtofte L, Holst JJ, Vilsbøll T, Knop FK (2011) Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes 60(12):3103–3109
doi: 10.2337/db11-0979
pubmed: 21984584
pmcid: 3219957
Yanagimachi T, Fujita Y, Takeda Y et al (2016) Pancreatic glucose-dependent insulinotropic polypeptide (GIP) (1–30) expression is upregulated in diabetes and PEGylated GIP(1–30) can suppress the progression of low-dose-STZ-induced hyperglycaemia in mice. Diabetologia 59(3):533–541. https://doi.org/10.1007/s00125-015-3842-y
doi: 10.1007/s00125-015-3842-y
pubmed: 26693710
Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W (1993) Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91(1):301–307. https://doi.org/10.1172/jci116186
doi: 10.1172/jci116186
pubmed: 8423228
pmcid: 330027
Chia CW, Odetunde JO, Kim W, Carlson OD, Ferrucci L, Egan JM (2014) GIP contributes to islet trihormonal abnormalities in type 2 diabetes. J Clin Endocrinol Metab 99(7):2477–2485. https://doi.org/10.1210/jc.2013-3994
doi: 10.1210/jc.2013-3994
pubmed: 24712564
pmcid: 4079310
Piteau S, Olver A, Kim SJ et al (2007) Reversal of islet GIP receptor down-regulation and resistance to GIP by reducing hyperglycemia in the Zucker rat. Biochem Biophys Res Commun 362(4):1007–1012. https://doi.org/10.1016/j.bbrc.2007.08.115
doi: 10.1016/j.bbrc.2007.08.115
pubmed: 17803965
Miyawaki K, Yamada Y, Ban N et al (2002) Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 8(7):738–742
doi: 10.1038/nm727
pubmed: 12068290
Gögebakan Ö, Andres J, Biedasek K et al (2012) Glucose-dependent insulinotropic polypeptide reduces fat-specific expression and activity of 11β-hydroxysteroid dehydrogenase type 1 and inhibits release of free fatty acids. Diabetes 61(2):292–300. https://doi.org/10.2337/db10-0902
doi: 10.2337/db10-0902
pubmed: 22179810
pmcid: 3266397
Timper K, Grisouard J, Sauter NS et al (2013) Glucose-dependent insulinotropic polypeptide induces cytokine expression, lipolysis, and insulin resistance in human adipocytes. Am J Physiol Endocrinol Metab 304(1):E1-13. https://doi.org/10.1152/ajpendo.00100.2012
doi: 10.1152/ajpendo.00100.2012
pubmed: 23092914
Nyberg J, Anderson MF, Meister B et al (2005) Glucose-dependent insulinotropic polypeptide is expressed in adult hippocampus and induces progenitor cell proliferation. J Neurosci 25(7):1816–1825. https://doi.org/10.1523/jneurosci.4920-04.2005
doi: 10.1523/jneurosci.4920-04.2005
pubmed: 15716418
pmcid: 6725940
Adriaenssens AE, Biggs EK, Darwish T et al (2019) Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake. Cell Metab 30(5):987-996.e986. https://doi.org/10.1016/j.cmet.2019.07.013
doi: 10.1016/j.cmet.2019.07.013
pubmed: 31447324
pmcid: 6838660
Bollag RJ, Zhong Q, Phillips P et al (2000) Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors. Endocrinology 141(3):1228–1235. https://doi.org/10.1210/endo.141.3.7366
doi: 10.1210/endo.141.3.7366
pubmed: 10698200
Zhong Q, Itokawa T, Sridhar S et al (2007) Effects of glucose-dependent insulinotropic peptide on osteoclast function. Am J Physiol Endocrinol Metab 292(2):E543-548. https://doi.org/10.1152/ajpendo.00364.2006
doi: 10.1152/ajpendo.00364.2006
pubmed: 17003233
Christensen MB, Lund AB, Jørgensen NR, Holst JJ, Vilsbøll T, Knop FK (2020) Glucose-dependent insulinotropic polypeptide (GIP) reduces bone resorption in patients with type 2 diabetes. J Endocr Soc 4(9):bvaa097. https://doi.org/10.1210/jendso/bvaa097
doi: 10.1210/jendso/bvaa097
pubmed: 32904711
pmcid: 7458112
Christensen MB, Lund A, Calanna S et al (2018) Glucose-dependent insulinotropic polypeptide (GIP) inhibits bone resorption independently of insulin and glycemia. J Clin Endocrinol Metab 103(1):288–294. https://doi.org/10.1210/jc.2017-01949
doi: 10.1210/jc.2017-01949
pubmed: 29099978
Pi-Sunyer X, Astrup A, Fujioka K et al (2015) A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 373(1):11–22. https://doi.org/10.1056/NEJMoa1411892
doi: 10.1056/NEJMoa1411892
pubmed: 26132939
Wilding JPH, Batterham RL, Calanna S et al (2021) Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 384(11):989–1002. https://doi.org/10.1056/NEJMoa2032183
doi: 10.1056/NEJMoa2032183
pubmed: 33567185
Rubino DM, Greenway FL, Khalid U et al (2022) Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes. JAMA 327(2):138–150. https://doi.org/10.1001/jama.2021.23619
doi: 10.1001/jama.2021.23619
pubmed: 35015037
pmcid: 8753508
Karagiannis T, Avgerinos I, Liakos A et al (2022) Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia 65(8):1251–1261. https://doi.org/10.1007/s00125-022-05715-4
doi: 10.1007/s00125-022-05715-4
pubmed: 35579691
pmcid: 9112245
Vadher K, Patel H, Mody R et al (2022) Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: an adjusted indirect treatment comparison. Diabetes Obes Metab 24(9):1861–1868. https://doi.org/10.1111/dom.14775
doi: 10.1111/dom.14775
pubmed: 35589616
pmcid: 9546430
Matza LS, Stewart KD, Landó LF, Patel H, Boye KS (2022) Exit interviews examining the patient experience in clinical trials of tirzepatide for treatment of type 2 diabetes. Patient Patient-Centered Outcomes Res 15(3):367–377. https://doi.org/10.1007/s40271-022-00578-8
doi: 10.1007/s40271-022-00578-8
Plat AW, Rasouli N, Peleshok J, Sapin H, Wilding J (2022) Change in body weight from baseline with tirzepatide: sex subgroup analysis of the SURPASS studies. Diabetes. https://doi.org/10.2337/db22-720-P
doi: 10.2337/db22-720-P
Wilding JPH, Kwan AYM, Maldonado JM, Wang H, Rasouli N (2022) Tirzepatide induces weight loss in patients with type 2 diabetes regardless of baseline BMI: a post hoc analysis of SURPASS-1 through SURPASS-5 studies. Diabetologia 65(Suppl 1):S289–S289
Patel H, Khunti K, Rodbard HW et al (2022) Tirzepatide-induced weight loss in type 2 diabetes is independent of nausea, vomiting, or diarrhoea. Diabetologia 65(Suppl 1):S290–S291
Gastaldelli A, Cusi K, Fernandez Lando L, Bray R, Brouwers B, Rodriguez A (2022) Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol 10(6):393–406. https://doi.org/10.1016/S2213-8587(22)00070-5
doi: 10.1016/S2213-8587(22)00070-5
pubmed: 35468325
Samms RJ, Coghlan MP, Sloop KW (2020) How may GIP enhance the therapeutic efficacy of GLP-1? Trends Endocrinol Metab 31(6):410–421. https://doi.org/10.1016/j.tem.2020.02.006
doi: 10.1016/j.tem.2020.02.006
pubmed: 32396843
Coskun T, Heise T, DeVries J et al (2022) Tirzepatide reduces appetite, energy intake and fat mass in people with type 2 diabetes. Diabetologia 65(Suppl 1):S288–S288
Samms RJ, Zhang G, He W et al (2022) Tirzepatide induces a thermogenic-like amino acid signature in brown adipose tissue. Mol Metab 64:101550. https://doi.org/10.1016/j.molmet.2022.101550
doi: 10.1016/j.molmet.2022.101550
pubmed: 35921984
pmcid: 9396640
Geisler CE, Antonellis MP, Trumbauer W et al (2023) Tirzepatide suppresses palatable food intake by selectively reducing preference for fat in rodents. Diabetes Obes Metab 25(1):56–67
doi: 10.1111/dom.14843
pubmed: 36054312
Rosenstock J, Wysham C, Frias JP et al (2021) Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet 398(10295):143–155. https://doi.org/10.1016/S0140-6736(21)01324-6
doi: 10.1016/S0140-6736(21)01324-6
pubmed: 34186022
Del Prato S, Kahn SE, Pavo I et al (2021) Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet 398(10313):1811–1824. https://doi.org/10.1016/S0140-6736(21)02188-7
doi: 10.1016/S0140-6736(21)02188-7
pubmed: 34672967
Dahl D, Onishi Y, Norwood P et al (2022) Effect of subcutaneous tirzepatide vs placebo added to titrated Insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA 327(6):534–545. https://doi.org/10.1001/jama.2022.0078
doi: 10.1001/jama.2022.0078
pubmed: 35133415
pmcid: 8826179
Heise T, Mari A, DeVries JH et al (2022) Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes Endocrinol 10(6):418–429. https://doi.org/10.1016/S2213-8587(22)00085-7
doi: 10.1016/S2213-8587(22)00085-7
pubmed: 35468322
Rawshani A, Rawshani A, Gudbjörnsdottir S (2017) Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med 377(3):300–301. https://doi.org/10.1056/NEJMc1706292
doi: 10.1056/NEJMc1706292
pubmed: 28723317
Halminen J, Sattar N, Rawshani A et al (2022) Range of risk factor levels, risk control, and temporal trends for nephropathy and end-stage kidney disease in patients with type 1 and type 2 diabetes. Diabetes Care 45(10):2326–2335. https://doi.org/10.2337/dc22-0926
doi: 10.2337/dc22-0926
pubmed: 35984439
Pearson-Stuttard J, Cheng YJ, Bennett J et al (2022) Trends in leading causes of hospitalisation of adults with diabetes in England from 2003 to 2018: an epidemiological analysis of linked primary care records. Lancet Diabetes Endocrinol 10(1):46–57. https://doi.org/10.1016/s2213-8587(21)00288-6
doi: 10.1016/s2213-8587(21)00288-6
pubmed: 34861153
pmcid: 8672063
Heerspink HJL, Sattar N, Pavo I et al (2022) Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol 10(11):774–785. https://doi.org/10.1016/s2213-8587(22)00243-1
doi: 10.1016/s2213-8587(22)00243-1
pubmed: 36152639
Sattar N, McGuire DK, Pavo I et al (2022) Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med 28(3):591–598. https://doi.org/10.1038/s41591-022-01707-4
doi: 10.1038/s41591-022-01707-4
pubmed: 35210595
pmcid: 8938269
Sabaté E, Sabaté E (2003) Adherence to long-term therapies: evidence for action. World Health Organization, Geneva
Krass I, Schieback P, Dhippayom T (2015) Adherence to diabetes medication: a systematic review. Diabet Med 32(6):725–737
doi: 10.1111/dme.12651
pubmed: 25440507
Khunti K, Seidu S, Kunutsor S, Davies M (2017) Association between adherence to pharmacotherapy and outcomes in type 2 diabetes: a meta-analysis. Diabetes Care 40(11):1588–1596
doi: 10.2337/dc16-1925
pubmed: 28801474
Lee DSU, Lee H (2022) Adherence and persistence rates of major antidiabetic medications: a review. Diabetol Metab Syndr 14(1):12
doi: 10.1186/s13098-022-00785-1
pubmed: 35033161
pmcid: 8761325
Bogner HR, Morales KH, de Vries HF, Cappola AR (2012) Integrated management of type 2 diabetes mellitus and depression treatment to improve medication adherence: a randomized controlled trial. Ann Family Med 10(1):15–22
doi: 10.1370/afm.1344
Rubin RR (2005) Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Am J Med 118(5):27–34
doi: 10.1016/j.amjmed.2005.04.012
Polonsky W, Fisher L, Hessler D, Bruhn D, Best J (2011) Patient perspectives on once-weekly medications for diabetes. Diabetes Obes Metab 13(2):144–149
doi: 10.1111/j.1463-1326.2010.01327.x
pubmed: 21199266
Matza LS, Boye KS, Stewart KD et al (2020) Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: a crossover study (PREFER). Diabetes Obes Metab 22(3):355–364
doi: 10.1111/dom.13902
pubmed: 31646727
Ruiz PLD, Stene LC, Bakken IJ, Håberg SE, Birkeland KI, Gulseth HL (2018) Decreasing incidence of pharmacologically and non-pharmacologically treated type 2 diabetes in Norway: a nationwide study. Diabetologia 61(11):2310–2318. https://doi.org/10.1007/s00125-018-4681-4
doi: 10.1007/s00125-018-4681-4
pubmed: 29995214
pmcid: 6182655
Koye DN, Ling J, Dibato J, Khunti K, Montvida O, Paul SK (2020) Temporal trend in young-onset type 2 diabetes—macrovascular and mortality risk: study of UK primary care electronic medical records. Diabetes Care 43(9):2208–2216. https://doi.org/10.2337/dc20-0417
doi: 10.2337/dc20-0417
pubmed: 32616608
Davies MJ, Aroda VR, Collins BS et al (2022) Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care 45(11):2753–2786. https://doi.org/10.2337/dci22-0034
doi: 10.2337/dci22-0034
pubmed: 36148880
pmcid: 10008140